Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease

Jun Ikari, Amy J. Nelson, Jannah Obaid, Alvaro Giron-Martinez, Kumiko Ikari, Fumihiko Makino, Shunichiro Iwasawa, Yoko Gunji, Maha Farid, Xingqi Wang, Hesham E Basma, Dawn Demeo, Carol Feghali-Bostwick, Olaf Holz, Klaus Rabe, Xiang-de Liu, Stephen I. Rennard

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Alterations in microRNA (miRNA) expression may contribute to COPD pathogenesis. In COPD, lung fibroblast repair functions are altered in multiple ways, including extracellular mediator release. Our prior study revealed miR-503 expression is decreased in COPD lung fibroblasts, although the exact role played by miR-503 is undetermined. The current study examined a role of miR-503 in cytokine, growth factor and fibronectin production by lung fibroblasts from patients with and without COPD. Primary adult lung fibroblasts were isolated from patients with or without COPD. MiR-503 expression and interleukin (IL)-6, -8, PGE2, HGF, KGF, VEGF and fibronectin release were examined with or without inflammatory cytokines, IL-1β and tumor necrosis factor (TNF)-α. MiR-503 expression was decreased in COPD lung fibroblasts. The expression of miR-503 was positively correlated with %FVC, %FEV1, and %DLco as well as IL-6, -8, PGE2, HGF, KGF, and VEGF in the absence or presence of IL-1ß/TNF-α. In addition, IL-8 and VEGF release from COPD lung fibroblasts were increased compared to those from control. Exogenous miR-503 inhibited VEGF release from primary adult and fetal lung fibroblasts but not IL-8 release. As expected, COPD fibroblasts proliferated more slowly than control fibroblasts. MiR-503 did not affect proliferation of either control or COPD lung fibroblasts. MiR-503 inhibition of VEGF protein production and mRNA was mediated by direct binding to the 3’ untranslated region of VEGF mRNA. Endogenous miR-503 was differently regulated by exogenous stimulants associated with COPD pathogenesis, including IL-1ß/TNF-α, TGF-ß1 and PGE2. Endogenous miR-503 inhibition augmented VEGF release by IL-1ß/TNF-α and TGF-ß1 but not by PGE2, demonstrating selectivity of miR-503 regulation of VEGF. In conclusions, reduced miR-503 augments VEGF release from lung fibroblasts from patients with COPD. Since VEGF contributes to disturbed vasculature in COPD, altered miR-503 production might play a role in modulating fibroblast-mediated vascular homeostasis in COPD.

Original languageEnglish (US)
Article numbere0184039
JournalPloS one
Volume12
Issue number9
DOIs
StatePublished - Sep 2017

Fingerprint

Pulmonary diseases
Fibroblasts
MicroRNAs
microRNA
respiratory tract diseases
Chronic Obstructive Pulmonary Disease
Vascular Endothelial Growth Factor A
fibroblasts
lungs
Lung
tumor necrosis factors
interleukin-1
Interleukin-1
Dinoprostone
Interleukin-8
Tumor Necrosis Factor-alpha
fibronectins
interleukin-8
Fibronectins
interleukin-6

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Ikari, J., Nelson, A. J., Obaid, J., Giron-Martinez, A., Ikari, K., Makino, F., ... Rennard, S. I. (2017). Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. PloS one, 12(9), [e0184039]. https://doi.org/10.1371/journal.pone.0184039

Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. / Ikari, Jun; Nelson, Amy J.; Obaid, Jannah; Giron-Martinez, Alvaro; Ikari, Kumiko; Makino, Fumihiko; Iwasawa, Shunichiro; Gunji, Yoko; Farid, Maha; Wang, Xingqi; Basma, Hesham E; Demeo, Dawn; Feghali-Bostwick, Carol; Holz, Olaf; Rabe, Klaus; Liu, Xiang-de; Rennard, Stephen I.

In: PloS one, Vol. 12, No. 9, e0184039, 09.2017.

Research output: Contribution to journalArticle

Ikari, J, Nelson, AJ, Obaid, J, Giron-Martinez, A, Ikari, K, Makino, F, Iwasawa, S, Gunji, Y, Farid, M, Wang, X, Basma, HE, Demeo, D, Feghali-Bostwick, C, Holz, O, Rabe, K, Liu, X & Rennard, SI 2017, 'Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease', PloS one, vol. 12, no. 9, e0184039. https://doi.org/10.1371/journal.pone.0184039
Ikari, Jun ; Nelson, Amy J. ; Obaid, Jannah ; Giron-Martinez, Alvaro ; Ikari, Kumiko ; Makino, Fumihiko ; Iwasawa, Shunichiro ; Gunji, Yoko ; Farid, Maha ; Wang, Xingqi ; Basma, Hesham E ; Demeo, Dawn ; Feghali-Bostwick, Carol ; Holz, Olaf ; Rabe, Klaus ; Liu, Xiang-de ; Rennard, Stephen I. / Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. In: PloS one. 2017 ; Vol. 12, No. 9.
@article{8365af02ce9443988149408d30d722c4,
title = "Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease",
abstract = "Alterations in microRNA (miRNA) expression may contribute to COPD pathogenesis. In COPD, lung fibroblast repair functions are altered in multiple ways, including extracellular mediator release. Our prior study revealed miR-503 expression is decreased in COPD lung fibroblasts, although the exact role played by miR-503 is undetermined. The current study examined a role of miR-503 in cytokine, growth factor and fibronectin production by lung fibroblasts from patients with and without COPD. Primary adult lung fibroblasts were isolated from patients with or without COPD. MiR-503 expression and interleukin (IL)-6, -8, PGE2, HGF, KGF, VEGF and fibronectin release were examined with or without inflammatory cytokines, IL-1β and tumor necrosis factor (TNF)-α. MiR-503 expression was decreased in COPD lung fibroblasts. The expression of miR-503 was positively correlated with {\%}FVC, {\%}FEV1, and {\%}DLco as well as IL-6, -8, PGE2, HGF, KGF, and VEGF in the absence or presence of IL-1{\ss}/TNF-α. In addition, IL-8 and VEGF release from COPD lung fibroblasts were increased compared to those from control. Exogenous miR-503 inhibited VEGF release from primary adult and fetal lung fibroblasts but not IL-8 release. As expected, COPD fibroblasts proliferated more slowly than control fibroblasts. MiR-503 did not affect proliferation of either control or COPD lung fibroblasts. MiR-503 inhibition of VEGF protein production and mRNA was mediated by direct binding to the 3’ untranslated region of VEGF mRNA. Endogenous miR-503 was differently regulated by exogenous stimulants associated with COPD pathogenesis, including IL-1{\ss}/TNF-α, TGF-{\ss}1 and PGE2. Endogenous miR-503 inhibition augmented VEGF release by IL-1{\ss}/TNF-α and TGF-{\ss}1 but not by PGE2, demonstrating selectivity of miR-503 regulation of VEGF. In conclusions, reduced miR-503 augments VEGF release from lung fibroblasts from patients with COPD. Since VEGF contributes to disturbed vasculature in COPD, altered miR-503 production might play a role in modulating fibroblast-mediated vascular homeostasis in COPD.",
author = "Jun Ikari and Nelson, {Amy J.} and Jannah Obaid and Alvaro Giron-Martinez and Kumiko Ikari and Fumihiko Makino and Shunichiro Iwasawa and Yoko Gunji and Maha Farid and Xingqi Wang and Basma, {Hesham E} and Dawn Demeo and Carol Feghali-Bostwick and Olaf Holz and Klaus Rabe and Xiang-de Liu and Rennard, {Stephen I.}",
year = "2017",
month = "9",
doi = "10.1371/journal.pone.0184039",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease

AU - Ikari, Jun

AU - Nelson, Amy J.

AU - Obaid, Jannah

AU - Giron-Martinez, Alvaro

AU - Ikari, Kumiko

AU - Makino, Fumihiko

AU - Iwasawa, Shunichiro

AU - Gunji, Yoko

AU - Farid, Maha

AU - Wang, Xingqi

AU - Basma, Hesham E

AU - Demeo, Dawn

AU - Feghali-Bostwick, Carol

AU - Holz, Olaf

AU - Rabe, Klaus

AU - Liu, Xiang-de

AU - Rennard, Stephen I.

PY - 2017/9

Y1 - 2017/9

N2 - Alterations in microRNA (miRNA) expression may contribute to COPD pathogenesis. In COPD, lung fibroblast repair functions are altered in multiple ways, including extracellular mediator release. Our prior study revealed miR-503 expression is decreased in COPD lung fibroblasts, although the exact role played by miR-503 is undetermined. The current study examined a role of miR-503 in cytokine, growth factor and fibronectin production by lung fibroblasts from patients with and without COPD. Primary adult lung fibroblasts were isolated from patients with or without COPD. MiR-503 expression and interleukin (IL)-6, -8, PGE2, HGF, KGF, VEGF and fibronectin release were examined with or without inflammatory cytokines, IL-1β and tumor necrosis factor (TNF)-α. MiR-503 expression was decreased in COPD lung fibroblasts. The expression of miR-503 was positively correlated with %FVC, %FEV1, and %DLco as well as IL-6, -8, PGE2, HGF, KGF, and VEGF in the absence or presence of IL-1ß/TNF-α. In addition, IL-8 and VEGF release from COPD lung fibroblasts were increased compared to those from control. Exogenous miR-503 inhibited VEGF release from primary adult and fetal lung fibroblasts but not IL-8 release. As expected, COPD fibroblasts proliferated more slowly than control fibroblasts. MiR-503 did not affect proliferation of either control or COPD lung fibroblasts. MiR-503 inhibition of VEGF protein production and mRNA was mediated by direct binding to the 3’ untranslated region of VEGF mRNA. Endogenous miR-503 was differently regulated by exogenous stimulants associated with COPD pathogenesis, including IL-1ß/TNF-α, TGF-ß1 and PGE2. Endogenous miR-503 inhibition augmented VEGF release by IL-1ß/TNF-α and TGF-ß1 but not by PGE2, demonstrating selectivity of miR-503 regulation of VEGF. In conclusions, reduced miR-503 augments VEGF release from lung fibroblasts from patients with COPD. Since VEGF contributes to disturbed vasculature in COPD, altered miR-503 production might play a role in modulating fibroblast-mediated vascular homeostasis in COPD.

AB - Alterations in microRNA (miRNA) expression may contribute to COPD pathogenesis. In COPD, lung fibroblast repair functions are altered in multiple ways, including extracellular mediator release. Our prior study revealed miR-503 expression is decreased in COPD lung fibroblasts, although the exact role played by miR-503 is undetermined. The current study examined a role of miR-503 in cytokine, growth factor and fibronectin production by lung fibroblasts from patients with and without COPD. Primary adult lung fibroblasts were isolated from patients with or without COPD. MiR-503 expression and interleukin (IL)-6, -8, PGE2, HGF, KGF, VEGF and fibronectin release were examined with or without inflammatory cytokines, IL-1β and tumor necrosis factor (TNF)-α. MiR-503 expression was decreased in COPD lung fibroblasts. The expression of miR-503 was positively correlated with %FVC, %FEV1, and %DLco as well as IL-6, -8, PGE2, HGF, KGF, and VEGF in the absence or presence of IL-1ß/TNF-α. In addition, IL-8 and VEGF release from COPD lung fibroblasts were increased compared to those from control. Exogenous miR-503 inhibited VEGF release from primary adult and fetal lung fibroblasts but not IL-8 release. As expected, COPD fibroblasts proliferated more slowly than control fibroblasts. MiR-503 did not affect proliferation of either control or COPD lung fibroblasts. MiR-503 inhibition of VEGF protein production and mRNA was mediated by direct binding to the 3’ untranslated region of VEGF mRNA. Endogenous miR-503 was differently regulated by exogenous stimulants associated with COPD pathogenesis, including IL-1ß/TNF-α, TGF-ß1 and PGE2. Endogenous miR-503 inhibition augmented VEGF release by IL-1ß/TNF-α and TGF-ß1 but not by PGE2, demonstrating selectivity of miR-503 regulation of VEGF. In conclusions, reduced miR-503 augments VEGF release from lung fibroblasts from patients with COPD. Since VEGF contributes to disturbed vasculature in COPD, altered miR-503 production might play a role in modulating fibroblast-mediated vascular homeostasis in COPD.

UR - http://www.scopus.com/inward/record.url?scp=85029098692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029098692&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0184039

DO - 10.1371/journal.pone.0184039

M3 - Article

C2 - 28880936

AN - SCOPUS:85029098692

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0184039

ER -